(Total Views: 613)
Posted On: 10/17/2023 1:42:30 PM
Post# of 155038
And will the new CEO continue the strategy laid out by Cyrus in the presentation last December or chart a new one?
It's been 15 months since the NIH grant toward a functional cure for HIV was announced and if preclinical work has continued to bolster the case Dr Sacha presented in that Dec call, does it still make sense to prioritize NASH over a potential cure?
Maybe that's where some kind of partitioning of the company comes into play with LivImmune but a new CEO may have the opportunity to take the company in whatever direction he or she ultimately thinks is best.
It's been 15 months since the NIH grant toward a functional cure for HIV was announced and if preclinical work has continued to bolster the case Dr Sacha presented in that Dec call, does it still make sense to prioritize NASH over a potential cure?
Maybe that's where some kind of partitioning of the company comes into play with LivImmune but a new CEO may have the opportunity to take the company in whatever direction he or she ultimately thinks is best.
(4)
(0)
